Kura Oncology, Inc. SEC filings KURA
Kura Oncology, Inc. has 806 filings in SEC EDGAR's recent list, going back to Feb 1, 2008. Its latest annual report, Form ARS, was filed on Apr 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 9, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | May 26, 2026 | — |
| DEFA14A | Additional proxy material | Apr 10, 2026 | — |
| DEF 14A | Proxy statement | Apr 10, 2026 | Jun 4, 2026 |
| DEFA14A | Additional proxy material | Apr 11, 2025 | — |
| DEF 14A | Proxy statement | Apr 11, 2025 | Jun 5, 2025 |
| DEFA14A | Additional proxy material | Apr 12, 2024 | — |
| DEF 14A | Proxy statement | Apr 12, 2024 | Apr 12, 2024 |
| DEFA14A | Additional proxy material | May 4, 2023 | — |
| DEFA14A | Additional proxy material | Apr 6, 2023 | — |
| DEF 14A | Proxy statement | Apr 6, 2023 | — |
| DEFA14A | Additional proxy material | Apr 28, 2022 | — |
| DEF 14A | Proxy statement | Apr 28, 2022 | Jun 21, 2022 |
| DEFA14A | Additional proxy material | Jun 4, 2021 | — |
| DEFA14A | Additional proxy material | Apr 29, 2021 | — |
| DEF 14A | Proxy statement | Apr 29, 2021 | Jun 22, 2021 |
| DEFA14A | Additional proxy material | Apr 28, 2020 | — |
| DEF 14A | Proxy statement | Apr 28, 2020 | Jun 24, 2020 |
| DEFA14A | Additional proxy material | Apr 29, 2019 | — |
| DEF 14A | Proxy statement | Apr 29, 2019 | Jun 25, 2019 |
| DEFA14A | Additional proxy material | Apr 26, 2018 | — |
| DEF 14A | Proxy statement | Apr 26, 2018 | Jun 7, 2018 |
| DEF 14A | Proxy statement | Apr 25, 2017 | Jun 9, 2017 |
| PRE 14A | Preliminary proxy statement | Mar 31, 2017 | Jun 9, 2017 |
| DEF 14A | Proxy statement | Apr 5, 2016 | May 12, 2016 |
| PRE 14A | Preliminary proxy statement | Mar 18, 2016 | May 12, 2016 |
| DEF 14C | Information statement | Mar 23, 2015 | Mar 23, 2015 |
| PRE 14C | Filing | Mar 13, 2015 | Mar 13, 2015 |
Showing 27 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KURA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422143
- Former names
- ZETA ACQUISITION CORP III (until Mar 10, 2015)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.